Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component of bone remodeling activity. Current antiresorptive agents are effective, but the effectiveness of some agents is limited by real or perceived intolerance, longterm adverse events (AEs), coexisting comorbidities, and inadequate long-term adherence. New antiresorptive therapies that may expand options for the prevention and treatment of osteoporosis include denosumab, combination of conjugated estrogen/ bazedoxifene and cathepsin K inhibitors. However, the long-term efficacy and AEs of these antiresorptive therapies need to be confirmed in studies with a longer follow-up period. (J Menopausal Med 2015;21:1-11)
Introduction
Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Because of reduced bone mineral density (BMD) and weakened bone structure, osteoporosis decreases bone resistance to low-energy trauma and increases bone fragility and fracture risk. The goal of osteoporosis treatment is to prevent fractures. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component of bone remodeling activity. The only anabolic agent currently available is teriparatide. Current antiresorptive agents are effective, but the effectiveness of some agents is limited by real or perceived intolerance, long-term adverse events (AEs), coexisting comorbidities, and inadequate long-term adherence. This review aims at providing an overview of the shortly after available or investigated new antiresorptive agents for osteoporosis.
Receptor Activator of Nuclear FactorKappa B (RANK) Ligand (RANKL) Inhibitor, Denosumab 
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upper thigh or the abdomen. 3 Denosumab inhibits numerous aspects of osteoclast differentiation and function by inhibiting the intracellular signal pathways that are activated by the RANKL/RANK binding, which results in decreased fractures and increased BMD. 4 RANKL presents ubiquitously throughout many tissues including cells of immune system such as activated T cells and B cells. 5 Since denosumab specifically binds RANKL, however, it is less likely to affect the immune system or other regulatory systems. Moreover, denosumab does not have the potential for autoimmunization against vital regulatory proteins and is characterized by a longer half-life which permits less frequent dosing. 6 
Pharmacokinetics and metabolism
The pharmacokinetics of denosumab is nonlinear with dose. 7 Studies with similar IgG antibodies showed that SC denosumab is absorbed by the lymphatic system with subsequent drainage into the vascular system. The bioavailability is about 50% to 100%. The clearance is probably by the reticuloendothelial system and no significant amount of denosumab seems to be filtered and excreted by the kidneys. SC administration is characterized by 3 stages:
a prolonged absorption phase with the maximum serum concentration (at 5 to 21 days post-dose); a long duration phase with half-life of a maximum of 32 days; a rapid terminal phase when serum concentration is lower than 1000 ng/mL. The magnitude of the initial response was similar among the doses, although the duration of the effect was dose-dependent. 6 2. Clinical studies on postmenopausal osteoporosis 
5) Effects of discontinuing denosumab on BMD
and levels of BTM For 256 postmenopausal women, 60 mg denosumab or a placebo was administered every 6 months for 2 years, followed by 2 years of discontinued treatment.
14 Denosumab discontinuation resulted in a decline in BMD at all sites during the first 12 month, followed by BMD stabilization during the next 12 months. After this 4-year period, the denosumab group maintained a higher BMD than the placebo group. Levels of BTMs were increased above baseline within 3 to 6 months of the initial 2-year treatment period.
By the end of the 4-year period, the levels of the BTMs had returned to baseline. The effects of denosumab were fully reversible over this time span, with no deleterious effect on bone micro-structure. Adherence was significantly greater with denosumab than alendronate (87.3% vs. 76.6%). Subject ratings for treatment preference and satisfaction were also significantly higher for denosumab than alendronate.
Safety
In osteoporosis clinical trials, denosumab was generally safe and well tolerated. Overall, there were no significant differences between subjects who received denosumab and those who received placebo in the total incidence of AEs, serious AEs, or discontinuation of treatment because of AEs.
Safety concerns with denosumab use include infections, cancer, skin reactions, hypocalcemia, osteonecrosis of the jaw (ONJ), and atypical femur fractures.
1) Infections, cancer and skin reactions
The major safety concerns with denosumab have been the potential risks for infection and malignancy because of the ubiquitous presence of RANKL throughout many tissues, including cells of the immune system such as activated T lymphocytes and B cells. 5 In the FREEDOM study, there was no increase in the overall risk of infection or cancer;
however, serious AEs of cutaneous infections such as cellulitis and erysipelas, occurred more in the denosumab group (< 0.1% vs. 0.3%, P = 0.002). 4 Dermatological AEs such as dermatitis, eczema and rashes also occurred at a significantly higher rate (8.2% vs. 10.8%, P < 0.0001) in the denosumab group. 4 In a post-hoc analysis of this study, serious AEs of infection such as skin, gastrointestinal, ear, urinary and cardiac valvular infection, were numerically higher in the denosumab group although the number of events was small and the differences between groups were not statistically significant. 10 The heterogeneous and no clear clinical pattern suggests that a relationship to time or duration of exposure to denosumab arguing against a causal relationship. 17 Finally, infectious events did not increase with long-term treatment of denosumab in the FREEDOM extension study. 
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given to patients with preexisting hypocalcemia until it is corrected.
3) ONJ
The FREEDOM study reported no case of ONJ in either denosumab or placebo group. 4 However, there have been eight adjudicated cases of ONJ in the FREEDOM extension study in the crossover and long-term groups. 4, 9 There has also been a low but similar incidence of ONJ in the oncology trials using monthly denosumab vs. monthly zoledronic acid (1.3% vs. 1.8% over 3 years). 21 Good oral hygiene and regular dental visits should be recommended for everyone. 
4) Atypical femur fractures

2) SMART-5 trial
The SMART-5 trial included an osteoporosis substudy in subjects who were 5 or less years of postmenopausal, had lumbar spine and total hip T-scores less than -2.5 at screening. 40 Subjects were randomized to CE 0. 4. Safety and tolerability CE/BZA was well tolerated win the SMART studies. The overall incidence of treatment emergent AEs among women treated CE/BZA was similar to placebo in all of the trials.
Rates of venous thromboembolism, ischemic stroke, and coronary heart disease event among women using CE 0.45/ BZA 20 mg were comparable to placebo. 40~42, 45 There were no cases of pulmonary embolism in any of the SMART trials.
Laboratory findings with CE/BZA have shown largely neutral or beneficial effects on lipids and coagulation markers. 41, 42 Cumulative amenorrhea rate and incidence of bleeding/ spotting are similar to placebo. when compared with balicatib and relacatib. 55 In preclinical studies, odanacatib presented good pharmacokinetic parameters such as minimal in vitro metabolism and long half-life, and oral bioavailability. 
Safety data from LOFT
The rates of AEs overall in LOFT were generally balanced between patients taking odanacatib and placebo. 58 Adjudicated morphea-like skin lesions occurred more frequently on odanacatib: in 12 patients in the odanacatib group (0.1%) and 3 patients in the placebo group (< 0.1%). These skin lesions resolved or improved after discontinuation of the study drug. 
Differences between odanacatib and other
antiresorptive agents Odanacatib has shown greater suppression of bone resorption than bone formation, suggesting dissociation between bone resorption and bone formation. 56, 57 The exact molecular mechanisms linking cathepsin K inhibition and bone formation remain largely unknown; however, they have been predicted to involve complex networks of cell to cell communications. Khosla 59 hypothesized that in the setting of odanacatib treatment, while the reduction in bone resorption would lead to a reduction in the release of growth factors from the bone matrix, direct communication between non-resorbing osteoclasts and osteoblasts through the ephrin 2-erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) system may not be affected.
The same may be true of coupling factors, if they are also secreted by non-resorbing osteoclasts. Thus, the net effect of odanacatib on bone formation could depend on offsetting the effects of the loss of growth factor release from bone matrix with the ongoing, perhaps enhanced, effects of coupling factors from the increased numbers of relatively healthy osteoclasts. Furthermore, different remodeling or modeling rates of specific bone surfaces could be linked to the compartment-specific action of odanacatib on bone formation. In trabecular bone, with its high remodeling rate, and where inhibition of bone resorption was associated with reduction in bone formation, the release of growth factors from the bone matrix may be particularly important. 60 On periosteal surfaces, however, where the remodeling rate is much lower and the activity is predominantly modeling, the direct stimulatory effects of osteoclasts on osteoblasts could be responsible for the increased periosteal bone formation and cortical thickness. J MM
